Remove 2024 Remove Leads Remove Side effects
article thumbnail

Improving stem cell transplantation success in high-risk blood cancers

European Pharmaceutical Review

These new findings, which are part of an ongoing Phase II study , will be presented at the 2024 American Society of Clinical Oncology (ASCO) meeting and the European Hematology Association ( Abstract #6503 ). They explained that cyclophosphamide “counteracts” graft vs. host disease (GVHD) , a serious side effect of transplantation.

article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.

article thumbnail

Bristol Myers Squibb licenses amyloid-beta antibody programme

European Pharmaceutical Review

. “I am very excited about the agreement with Bristol Myers Squibb.With the BrainTransporter technology, BioArctic has the capability to lead in the design and development of the next generation of treatments for various brain disorders, offering the potential of faster uptake, improved efficacy, less side effects and lower doses for the benefit (..)

article thumbnail

New Nkarta data backs up natural killer approach to cancer treatment

pharmaphorum

One leading proponent of the approach – South San Francisco’s Nkarta – has just reported new results from an early-stage trial of one of its CAR-NK therapies that will likely add to the enthusiasm for the field. Those will get underway in 2024.

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

article thumbnail

What GLP-1 drugs mean for medtech

Clarivate

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. Device-based treatments for comorbidities associated with obesity will also see an impact. You can register for the webinar here.